Evidence map›Paper›PMID 32915357›Full record

ArticleGlycoconjugate journal2020

APOL1 polymorphism modulates sphingolipid profile of human podocytes.

Manuela Valsecchi, Valentina Cazzetta, Ferdinando Oriolo, Xiqian Lan, Rocco Piazza, Moin A Saleem, Pravin C Singhal, Domenico Mavilio, Joanna Mikulak, Massimo Aureli

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Glycoconjugate journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. A lipid atlas of the human kidney.Science advances · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Gangliosides in Podocyte Biology and Disease.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

Manuela ValsecchiDepartment of Medical Biotechnologies and Translational Medicine (BioMeTra), University of Milan, Milan, Italy.
Valentina CazzettaDepartment of Medical Biotechnologies and Translational Medicine (BioMeTra), University of Milan, Milan, Italy.
Ferdinando OrioloUnit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center - IRCCS, Rozzano, MI, Italy.
Xiqian LanKey Laboratory for Aging and Regenerative Medicine, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China.
Rocco PiazzaDepartment of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
Moin A SaleemPediatric Academic Renal Unit, University of Bristol, Bristol, UK.
Pravin C SinghalInstitute of Molecular Medicine, Feinstein Institute for Medical Research and Zucker School of Medicine at Hofstra-Northwell, Hempstead, NY, USA.
Domenico MavilioDepartment of Medical Biotechnologies and Translational Medicine (BioMeTra), University of Milan, Milan, Italy.
Joanna MikulakDepartment of Medical Biotechnologies and Translational Medicine (BioMeTra), University of Milan, Milan, Italy.
Massimo AureliDepartment of Medical Biotechnologies and Translational Medicine (BioMeTra), University of Milan, Milan, Italy. massimo.aureli@unimi.it.ORCID 0000-0003-1916-2440
Humanitas University · ITUniversity of Milan · ITFeinstein Institute for Medical Research · USSouthwest Medical University · CNUniversity of Bristol · GBUniversity of Milano-Bicocca · IT

Funding

APOL1 in Diabetic PodocytopathyR01DK118017 · NIDDK · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI SINGHAL, PRAVIN C · 2018 to 2021
$2.0M
NIDDK NIH HHS R01 DK118017
6 · The paper itself

Abstract

Apolipoprotein L1 (APOL1) wild type (G0) plays a role in the metabolism of sphingolipids, glycosphingolipids, sphingomyelin and ceramide, which constitute bioactive components of the lipid rafts (DRM). We asked whether APOL1 variants (APOL1-Vs) G1 and G2 carry the potential to alter the metabolism of sphingolipids in human podocytes. The sphingolipid pattern in HPs overexpressing either APOL1G0 or APOL1-Vs was analysed by using a thin mono- and bi-dimensional layer chromatography, mass-spectrometry and metabolic labelling with [1-

Indexed as

Apolipoprotein L1Cell MembraneGene Expression RegulationGlycoside HydrolasesHumansMetabolismPodocytesPolymorphism, GeneticSphingolipidsAPOL1 protein, humanApolipoprotein L1Glycoside HydrolasesSphingolipidsAPOL1APOL1 polymorphismHIVANLipid raftsPlasma membranePodocytesSphingolipids

Identifiers

PMID32915357
PMCPMC7679335
OpenAlexW3086246061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.